These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 15041384)

  • 1. Total cholesterol correlates with cyclosporine C2 levels in kidney transplant recipients under maintenance immunosuppression.
    Cardinal H; Barama AA; Fradet V; Lallier M; Lévesque R; St Louis G; Hébert MJ; Girardin C; Pâquet M; Daloze P
    Transplant Proc; 2004 Mar; 36(2 Suppl):448S-450S. PubMed ID: 15041384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of C0 and C2 levels with cyclosporine side effects in kidney transplantation.
    Rodrigo E; Ruiz JC; Angeles de Cos M; Ruiz J; Gago M; Piñera C; Sánchez B; González-Cotorruelo J; Gómez-Alamillo C; Arias M
    Transplant Proc; 2009; 41(6):2328-31. PubMed ID: 19715910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclosporine dose reduction in stable renal transplant patients with high C2 level: simplified method of single C2 measurement and individualization of C0 target.
    Higgins RM; Kanji H; Hernon M; Harrison P; Lam FT; Kashi SH
    Transpl Int; 2005 Jul; 18(7):806-10. PubMed ID: 15948859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of cyclosporine concentrations 2 hours post-dose determined using 3 different methods and trough level in pediatric renal transplantation.
    Rodríguez E; Delucchi MA; Cano F; Valdebenito S; Castillo MC; Villegas R
    Transplant Proc; 2005 Oct; 37(8):3354-7. PubMed ID: 16298594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of C0 and C2 levels with lipid profiles in adolescent renal transplant recipients in the early and late posttransplant periods.
    Soylu A; Kavukçu S; Türkmen MA; Kasap B; Soylu A; Bora S; Gülay H
    Transplant Proc; 2006 Jun; 38(5):1286-9. PubMed ID: 16797283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C2 is superior to C0 as predictor of renal toxicity and rejection risk profile in stable heart transplant recipients.
    Caforio AL; Tona F; Piaserico S; Gambino A; Feltrin G; Fortina AB; Angelini A; Alaibac M; Bontorin M; Calzolari D; Peserico A; Thiene G; Iliceto S; Gerosa G
    Transpl Int; 2005 Jan; 18(1):116-24. PubMed ID: 15612993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclosporine trough (C0) and 2-hour postdose (C2) levels: which one is a predictor of graft loss?
    Nemati E; Einollahi B; Taheri S; Moghani-Lankarani M; Kalantar E; Simforoosh N; Nafar M; Saadat AR
    Transplant Proc; 2007 May; 39(4):1223-4. PubMed ID: 17524938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C2 is an age-independent parameter for optimal cyclosporine exposure in long-term kidney transplant recipients.
    Ferraresso M; Citterio F; Ghio L; Romagnoli J; Edefonti A; Berardinelli L; Castagneto M
    Transplant Proc; 2004 Nov; 36(9):2656-8. PubMed ID: 15621115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experience with cyclosporine: approaching the therapeutic window for C2 levels in maintenance kidney transplant recipients.
    Di Paolo S; Teutonico A; Infante B; Stallone G; Schena A; Grandaliano G; Battaglia M; Di Tonno P; Schena FP
    Transplant Proc; 2004 Mar; 36(2 Suppl):434S-436S. PubMed ID: 15041381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C2 monitoring in maintenance renal transplant recipients: is it worthwhile?
    Midtvedt K; Fauchald P; Bergan S; Høieggen A; Hallan S; Svarstad E; Bergrem H; Eriksen BO; Pfeffer PF; Dalen I; Leivestad T
    Transplantation; 2003 Oct; 76(8):1236-8. PubMed ID: 14578761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A survey to determine the blood concentration of cyclosporine 2 hours postdose in stable renal transplant patients.
    Jorga A; Holt DW; Yaqoob M; Whittaker C; Johnston A
    Transplant Proc; 2004 Dec; 36(10):3239-41. PubMed ID: 15686737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-hour postdose concentration: a reliable marker for cyclosporine exposure in adolescents with stable renal transplants.
    John U; Ullrich S; Roskos M; Misselwitz J
    Transplant Proc; 2005 Apr; 37(3):1608-11. PubMed ID: 15866686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between cyclosporine concentrations at 2 hours post-dose and clinical outcomes in de novo lung transplant recipients.
    Akhlaghi F; Gonzalez L; Trull AK
    J Heart Lung Transplant; 2005 Dec; 24(12):2120-8. PubMed ID: 16364860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of the absorption profile of cyclosporine A in renal transplant recipients: a longitudinal study of the de novo and maintenance phases.
    Büchler M; Chadban S; Cole E; Midtvedt K; Thervet E; Prestele H; Keown P
    Nephrol Dial Transplant; 2006 Jan; 21(1):197-202. PubMed ID: 16204301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of the pharmacokinetics of cyclosporine in patients following long-term administration after a kidney transplant: comparison of Neoral and Sandimmune.
    Takahara S; Ichimaru N; Kojima Y; Namba Y; Toki K; Shi Y; Yoshimura K; Matsumiya K; Nonomura N; Okuyama A
    Transplant Proc; 2004 Mar; 36(2 Suppl):456S-460S. PubMed ID: 15041387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical benefits of neoral C2 monitoring in the long-term management of renal transplant recipients.
    Cole E; Maham N; Cardella C; Cattran D; Fenton S; Hamel J; O'Grady C; Smith R
    Transplantation; 2003 Jun; 75(12):2086-90. PubMed ID: 12829917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of cyclosporine pharmacokinetic parameters to facilitate conversion from C0 to C2 monitoring in heart transplant recipients.
    Davies RA; Veinot JP; Williams K; Haddad H; Baker A; Donaldson J; Pugliese C; Struthers C; Masters RG; Hendry PJ; Mesana T
    Transplant Proc; 2007 Dec; 39(10):3334-9. PubMed ID: 18089382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single time point measurement by C2 or C3 is highly predictive in cyclosporine area under the curve estimation immediately after lung transplantation.
    Hangler HB; Ruttmann E; Geltner C; Bucher B; Nagiller J; Laufer G; Mueller LC
    Clin Transplant; 2008; 22(1):35-40. PubMed ID: 18217903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term comparative results of C0 and C2 monitoring of CyA in renal transplanted patients.
    Paydaş S; Balal M; Sertdemir Y; Seyrek N; Karayaylali I
    Ren Fail; 2005; 27(4):409-13. PubMed ID: 16060128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of late conversion from C0 to C2 monitoring of microemulsified cyclosporine in pediatric living donor liver transplant recipients.
    Takatsuki M; Chen CL; Chen YS; Wang CC; Lin CC; Yang CH; Yong CC; Liu YW
    Clin Transplant; 2004 Dec; 18(6):694-9. PubMed ID: 15516246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.